Press releases
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.56 |
---|---|
High | 3.56 |
Low | 3.33 |
Bid | 3.28 |
Offer | 3.40 |
Previous close | 3.39 |
Average volume | 66.67 |
---|---|
Shares outstanding | 150.65m |
Free float | 149.61m |
P/E (TTM) | -- |
Market cap | 557.42m USD |
EPS (TTM) | -0.6156 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 18:31 BST.
More ▼